Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00236145 | Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain | PHASE3 | COMPLETED | - | — | — | Jun 1, 2004 | - | Jan 29, 2013 | - | — |
| Name | Type | Description |
|---|---|---|
| ACTIQ (Oral transmucosal fentanyl citrate) | DRUG | - |
Inclusion Criteria: Patients are included in the study if all of the following criteria are met: * the patient is at least 18 years old * women must be surgically sterile, 2 years postmenopausal, or if of child-bearing potential, must use a medically accepted method of birth control (ie, barrier me...